nebulized ketamine
Phase 3Small molecule
nebulized ketamine is one of 46 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Daliresp
AstraZenecaPhase 3
Latuda
SSunovion Respiratory Development Inc.
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Bupropion XL
GSKPhase 3
Levophed
GGeneral Hospital of Ningxia Medical University
Phase 3
SPD489
TakedaPhase 3
Venlafaxine ER
PfizerPhase 3
MK0869, Aprepitant
Merck & Co.Phase 3
Antidepressant Therapy
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dexmedetomidine1 trial
Premedication With Nebulized Ketamine,Dexmedetomidine Versus Midazolam in Oncologic Preschool Children
Completed·—·Phase 1/2·NCT02935959·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for nebulized ketamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTheresa Jacob, PhD, MPH